Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

BBI Solutions Increases Capacity for Cell Culture Native Human Transferrin Production

publication date: Jul 12, 2017
 | 
author/source: BBI Solutions

BBI’s human transferrin

BBI Solutions (BBI) has invested into its facilities and resource in order to increase the capacity of cell culture transferrin production by up to 40%.

Stephane Argivier, BBI’s Director of Product Management said “demand for our cell culture grade transferrin was growing at such a rate that we had reached our full capacity. In response to market demand we saw the opportunity to increase our capacity to meet the needs of our customers and provide room for growth.”

Human transferrin is a natural and often essential component to promote cell growth in many cell culture applications and is frequently used in serum free media, where it acts as an iron transporter.

BBI have been manufacturing human holo, apo and sidero grades of transferrin for over 10 years. In this time, growth in the cell culture market has been noticeable and it is only set to continue, as forecasts show it to be worth 18.63 Billion USD by 2020 (CAGR 10.5%)¹.

Factors triggering growth include increasing incidence of chronic diseases, increasing regulatory approvals for cell culture based vaccines, funding for cell-based research and technological advancements in cell culture products¹.

The increase in BBI’s production capacity has seen substantial improvements to the manufacturing facilities at their site in Sittingbourne, England. Investing £150K into new machinery, and increasing resource capabilities.

BBI’s human transferrin is manufactured under the ISO 13485 quality management system. BBI provide high specification material at large scale and with excellent batch-to-batch consistency. The human transferrin is pasteurised and filtered at 0.2µm to guarantee low mycoplasma and low bioburden. BBI can also control many other parameters, such as moisture and iron levels, to meet customer’s specifications and requirements.


more about BBI solutions


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events